1. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016) Authors: Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016) Authors: Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016) Authors: Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia Masvidal; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine A.; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy A.;... Journal: Journal for immunotherapy of cancer Issue: Volume 4(2016)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 384 A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas. (9th November 2020) Authors: Prawira, Amy; Coward, Jermaine; Mislang, Anna; Nagrial, Adnan; Gan, Hui; Jin, Xiaoping; Li, Baiyong; Wang, Zhongmin Maxwell; Kwek, Kon Yew; Xia, Dennis; Xia, Yu Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A409 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 384 A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas. (10th December 2020) Authors: Prawira, Amy; Coward, Jermaine; Mislang, Anna; Nagrial, Adnan; Gan, Hui; Jin, Xiaoping; Li, Baiyong; Wang, Zhongmin Maxwell; Kwek, Kon Yew; Xia, Dennis; Xia, Yu Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM). (11th November 2019) Authors: Lassman, Andrew; Pugh, Stephanie; Wang, Tony; Aldape, Kenneth; Gan, Hui; Preusser, Matthias; Vogelbaum, Michael; Sulman, Erik; Won, Minhee; Zhang, Peixin; Moazami, Golnaz; Macsai, Marian; Gilbert, Mark; Bain, Earle; Blot, Vincent; Ansell, Peter; Samanta, Suvajit; Kundu, Madan; Seidel, Clemens; De... Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. ATIM-23. PRELIMINARY FINDINGS OF A PHASE I SAFETY AND BIOIMAGING TRIAL OF KB004 (IFABOTUZUMAB) IN PATIENTS WITH GLIOBLASTOMA. (11th November 2019) Authors: Gan, Hui; Cher, Lawrence; Inglis, Po; Lwin, Zarnie; Lau, Eddie; Ackermann, Uwe; Coombs, Nicole; Remen, Kirsten; Guo, Nancy; Ting Lee, Sze; Gong, Sylvia; Palmer, Jodie; Pathmaraj, Kunthi; O'Keefe, Graeme; Scott, Fiona; Day, Bryan; Boyd, Andrew; Thomas, Paul; Durrant, Cameron; Scott, Andrew Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). (5th November 2018) Authors: Reardon, David; Kaley, Thomas; Dietrich, Jorg; Clarke, Jennifer; Dunn, Gavin; Lim, Michael; Cloughesy, Tim; Gan, Hui; Park, Andrew; Schwarzenberger, Paul; Ricciardi, Toni; Macri, Mary; Ryan, Aileen; Venhaus, Ralph Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. BRCC3 promotes activation of the NLRP6 inflammasome following cerebral ischemia/reperfusion (I/R) injury in rats. (21st June 2021) Authors: Huang, Xiaohuan; Gan, Hui; Tan, Junyi; Wang, Tingting; Zhao, Jing; Zhao, Yong Journal: Neuroscience letters Issue: Volume 756(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study. Issue 4 (13th July 2020) Authors: Rosenthal, Mark; Clement, Paul M; Campone, Mario; Gil-Gil, Miguel J; DeGroot, John; Chinot, Olivier; Idbaih, Ahmed; Gan, Hui; Raizer, Jeffrey; Wen, Patrick Yung; Pineda, Estela; Donnet, Valerie; Mills, David; El-Hashimy, Mona; Mason, Warren Journal: ESMO open Issue: Volume 5:Issue 4(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗